What did @myriamestrella8 actually say?
She lost over 110 pounds on a GLP-1 medication and came with five self-described regrets: not eating protein before injecting, not drinking enough water, sticking to one injection site, waiting too long to start, and not using Mochi Health sooner. This is a sponsored post, disclosed via hashtag and referral code, so her endorsement of Mochi as "the cheapest GLP-1 company" carries a financial incentive worth keeping in mind. The personal tips, though, are mostly separate from the ad pitch and deserve their own look.
She frames these as things "people don't talk about," which isn't entirely accurate. Patient communities, clinical nurses, and telehealth onboarding guides have covered all of these. But packaging common sense into relatable content is not the same as spreading misinformation, and her delivery is honest enough to take seriously.
Does the science back this up?
Mostly, yes, with some caveats. The protein-before-injection claim has no dedicated clinical trial behind it, but it's not implausible. The injection site rotation claim, though, is genuinely supported by pharmacokinetic data. And the water advice is basic but legitimate.
On protein: GLP-1 receptor agonists slow gastric emptying, which is partly why they suppress appetite but also why nausea is common early on, particularly on an empty stomach. Having food in your stomach, especially protein, which digests more slowly than simple carbs, may buffer gastric irritation. No randomized trial has specifically tested "protein bar 30 minutes before semaglutide," but clinical guidance from the manufacturer's prescribing information does suggest taking injections with food can help with GI tolerability.
On injection sites: A 2022 pharmacokinetic review (Thakur et al., Obesity Reviews) confirmed that subcutaneous absorption rates vary meaningfully by site, with abdominal tissue generally showing more consistent absorption than thigh in some patients. Rotating sites is standard clinical advice and she's right that a plateau can sometimes reflect absorption variability, not true pharmacological resistance.
On hydration: GLP-1 medications reduce appetite and food intake broadly, including fluids from food. Constipation is one of the most commonly reported side effects in trials, appearing in roughly 5-7% of semaglutide patients (Wilding et al., 2021, NEJM). Water helps. That's not a hot take, but it's correct.
What did they get wrong (or right)?
The injection site rotation causing a "stall" is the claim that deserves the most scrutiny. She's right that site rotation matters, but attributing a two-week weight loss plateau entirely to injection site is an oversimplification. Weight loss plateaus on GLP-1s are multifactorial. Hormonal adaptation, caloric intake creep, muscle loss, and metabolic compensation all play roles.
She also calls Mochi "the cheapest GLP-1 company," which is unverifiable as stated. Telehealth GLP-1 pricing fluctuates, varies by state, and depends on whether the product is compounded or brand-name. Compounded semaglutide and brand-name Wegovy are not equivalent products. The FDA does not recognize them as interchangeable, and quality control in compounding pharmacies varies. She doesn't distinguish between these, which matters.
What she got right: the fear-based delay is real and clinically documented. Patient hesitancy around GLP-1 initiation is a recognized barrier to care. Her "I just took it and it changed my life" framing is anecdotal, but the emotional truth of it reflects what adherence research shows: people who delay often miss early benefit windows when metabolic response tends to be strongest.
What should you actually know?
A few things she didn't mention are worth knowing before you sign up anywhere. First, GLP-1 medications require ongoing medical supervision. Monthly check-ins, which she mentions as a Mochi benefit, are genuinely important, not a perk. Dose adjustments, side effect monitoring, and screening for contraindications like a personal or family history of medullary thyroid carcinoma require actual clinical judgment.
Second, the protein tip has a smarter framing: it's less about the bar and more about not injecting on a completely empty stomach. The broader principle, eat something before your injection day, is reasonable for GI tolerability.
Third, if you're considering a telehealth GLP-1 platform, ask specifically whether you're being prescribed compounded or brand-name medication, which pharmacy is fulfilling it, and what happens to your care if you stop paying. These are questions this video doesn't raise and that any legitimate platform should answer clearly before you hand over a credit card number.